|
|
|
International Clinical Trials
|
“Today, 47 million people live with dementia worldwide, more than the population of Spain. This number is projected to increase to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. The total estimated worldwide cost of dementia is US$818 billion, and it will become a trillion dollar disease by 2018” (1).
Because of the social impact of this chronic neurodegenerative disease, it has become a major target for new therapies and, together with Parkinson’s, accounts for approximately a third of all neurological trials initiated over the past five years (2). Despite this, the success of new medicines in the area is poor. At present, the only products on the market are Cholinesterase inhibitors and N-methyl-D-asparate (NMDA) antagonists, providing symptomatic therapy. Consequently, the drive for diseasemodifying treatments is huge, and, despite major setbacks for drugs in trials to date, in 2016, 51 Alzheimer’s trials were initiated compared to five in 2002 (3,4). Dominantly Inherited Alzheimer Network Trial (DIAN-TU) represents a new frontier for assessing the impact of disease-modifying drugs as it targets patients with a genetic predisposition and starts treatment prophylactically.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
ACG to Showcase its Range of Capsules and Engineering Solutions at Supply Side West, Las Vegas
ACG, the only supplier in the world offering end-to-end manufacturing solutions for the pharmaceutical and the nutraceutical industries, will be exhibiting its wide range of Engineering and Capsules solutions at this year’s Supply Side West, Las Vegas. At ACG’s booth, the visitors will be able to see the synergies created with coupling ACG’s Capsules and Engineering products, thereby leveraging the many benefits of integrated manufacturing.
More info >> |
|
 |
White Papers |
 |
|
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology
European Society for Medical Oncology (ESMO)
The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >> |
|
 |
Industry Events |
 |
14th Annual Biomarkers Congress
21-22 February 2019, Manchester Central Convention Complex, UK
Oxford Global is proud to present for the 14th year our
flagship Biomarkers Congress, taking place 21 – 22 February
2019 in Manchester, UK. An updated programme ensures you will benefit
from talks on the latest strategies and technologies impacting growth in
the biomarker industry.
More info >> |
|
|
